Prof. Dr. Beat Thürlimann
First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88
Thürlimann B, Fey M, Senn H, Cavalli F, Jungi W, Goldhirsch A, Castiglione-Gertsch M, Bacchi M, Beretta K, Löhnert T. First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996; 7:471-9.
01.07.1996First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88
01.07.1996Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996; 7:471-9
Thürlimann Beat, Fey M, Senn H J, Cavalli F, Jungi W F, Goldhirsch A, Castiglione-Gertsch M, Bacchi M, Beretta K, Löhnert T
The changing approach to the treatment of early breast cancer
Thürlimann B, Senn H. The changing approach to the treatment of early breast cancer. The New England journal of medicine 1996; 334:1397-9.
23.05.1996The changing approach to the treatment of early breast cancer
23.05.1996The New England journal of medicine 1996; 334:1397-9
Thürlimann Beat, Senn H J
Causes and treatment of bone pain of malignant origin
Thürlimann B, de Stoutz N. Causes and treatment of bone pain of malignant origin. Drugs 1996; 51:383-98.
01.03.1996Causes and treatment of bone pain of malignant origin
01.03.1996Drugs 1996; 51:383-98
Thürlimann Beat, de Stoutz N D
A phase II trial of 5-fluorouracil and 1-leucovorin in patients with metastatic colorectal cancer
Erlichman C, Fine S, Kerr I, Hoffmann W, Gorg C, Schmoll H, Preusser P, Thürlimann B, Gustavsson B. A phase II trial of 5-fluorouracil and 1-leucovorin in patients with metastatic colorectal cancer. American journal of clinical oncology 1996; 19:26-31.
01.02.1996A phase II trial of 5-fluorouracil and 1-leucovorin in patients with metastatic colorectal cancer
01.02.1996American journal of clinical oncology 1996; 19:26-31
Erlichman C, Fine S, Kerr I, Hoffmann W, Gorg C, Schmoll H J, Preusser P, Thürlimann Beat, Gustavsson B
Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy
Pecherstorfer M, Huss H, van Eijkeren M, Steinhauer E, Tubiana-Hulin M, Thürlimann B, Clemens M, Degardin M, Manegold C, Body J, Herrmann Z, Thiébaud D. Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996; 14:268-76.
01.01.1996Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy
01.01.1996Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996; 14:268-76
Pecherstorfer M, Huss H J, van Eijkeren M, Steinhauer E U, Tubiana-Hulin M, Thürlimann Beat, Clemens M R, Degardin M, Manegold C, Body J J, Herrmann Z, Thiébaud D
Dexverapamil to overcome epirubicin resistance in advanced breast cancer
Thürlimann B, Hartlapp J, Gastl G, Schumacher K, Schernhammer E, Schüller J, Mross K, Greiner J, Kröger N, Kupper H. Dexverapamil to overcome epirubicin resistance in advanced breast cancer. Journal of cancer research and clinical oncology 1995; 121 Suppl 3:R3-6.
01.01.1995Dexverapamil to overcome epirubicin resistance in advanced breast cancer
01.01.1995Journal of cancer research and clinical oncology 1995; 121 Suppl 3:R3-6
Thürlimann Beat, Hartlapp J, Gastl G, Schumacher K, Schernhammer E, Schüller J, Mross K, Greiner J, Kröger N, Kupper H
Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine. Swiss Group for Clinical Cancer Research (SAKK)
Joss R, Stahel R, Martinelli G, Cerny T, Thürlimann B, Leyvraz S, Bacchi M, Hürny C, Alberto P, Ludwig C. Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine. Swiss Group for Clinical Cancer Research (SAKK). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995; 6:41-8.
01.01.1995Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine. Swiss Group for Clinical Cancer Research (SAKK)
01.01.1995Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995; 6:41-8
Joss R A, Stahel R, Martinelli G, Cerny T, Thürlimann Beat, Leyvraz S, Bacchi M, Hürny C, Alberto P, Ludwig C
First isolated locoregional recurrence following mastectomy for breast cancer: results of a phase III multicenter study comparing systemic treatment with observation after excision and radiation. Swiss Group for Clinical Cancer Research
Borner M, Cavalli F, Thürlimann B, Jungi W, Castiglione M, Harder F, Greiner R, Goldhirsch A, Bacchi M, Obrecht J. First isolated locoregional recurrence following mastectomy for breast cancer: results of a phase III multicenter study comparing systemic treatment with observation after excision and radiation. Swiss Group for Clinical Cancer Research. J Clin Oncol 1994; 12:2071-7.
01.10.1994First isolated locoregional recurrence following mastectomy for breast cancer: results of a phase III multicenter study comparing systemic treatment with observation after excision and radiation. Swiss Group for Clinical Cancer Research
01.10.1994J Clin Oncol 1994; 12:2071-7
Borner M, Cavalli F, Thürlimann Beat, Jungi W F, Castiglione M, Harder F, Greiner R, Goldhirsch A, Bacchi M, Obrecht J P
Ondansetron plus dexamethasone is superior to ondansetron alone in the prevention of emesis in chemotherapy-naive and previously treated patients. Swiss Group for Clinical Cancer Research (SAKK)
Joss R, Bacchi M, Buser K, Kirchner V, Neuenschwander H, Orth B, Aapro M, Thürlimann B. Ondansetron plus dexamethasone is superior to ondansetron alone in the prevention of emesis in chemotherapy-naive and previously treated patients. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 1994; 5:253-8.
01.03.1994Ondansetron plus dexamethasone is superior to ondansetron alone in the prevention of emesis in chemotherapy-naive and previously treated patients. Swiss Group for Clinical Cancer Research (SAKK)
01.03.1994Ann Oncol 1994; 5:253-8
Joss R A, Bacchi M, Buser K, Kirchner V, Neuenschwander H, Orth B, Aapro M S, Thürlimann Beat
Pamidronate for pain control in patients with malignant osteolytic bone disease: a prospective dose-effect study
Thürlimann B, Morant R, Jungi W, Radziwill A. Pamidronate for pain control in patients with malignant osteolytic bone disease: a prospective dose-effect study. Support Care Cancer 1994; 2:61-5.
01.01.1994Pamidronate for pain control in patients with malignant osteolytic bone disease: a prospective dose-effect study
01.01.1994Support Care Cancer 1994; 2:61-5
Thürlimann Beat, Morant R, Jungi W F, Radziwill A
Present status and potential role of high-dose adjuvant chemotherapy in breast cancer with poor prognosis
Thürlimann B. Present status and potential role of high-dose adjuvant chemotherapy in breast cancer with poor prognosis. Arch Gynecol Obstet 1994; 255 Suppl 2:S379-80.
01.01.1994Present status and potential role of high-dose adjuvant chemotherapy in breast cancer with poor prognosis
01.01.1994Arch Gynecol Obstet 1994; 255 Suppl 2:S379-80
Thürlimann Beat
Progress in the treatment and palliation of advanced breast cancer: does the dose of pamidronate determine its effects?
Thürlimann B. Progress in the treatment and palliation of advanced breast cancer: does the dose of pamidronate determine its effects?. Ann Oncol 1994; 5 Suppl 7:S45-7.
01.01.1994Progress in the treatment and palliation of advanced breast cancer: does the dose of pamidronate determine its effects?
01.01.1994Ann Oncol 1994; 5 Suppl 7:S45-7
Thürlimann Beat
Plicamycin and pamidronate in symptomatic tumor-related hypercalcemia: a prospective randomized crossover trial
Thürlimann B, Waldburger R, Senn H, Thiébaud D. Plicamycin and pamidronate in symptomatic tumor-related hypercalcemia: a prospective randomized crossover trial. Ann Oncol 1992; 3:619-23.
01.09.1992Plicamycin and pamidronate in symptomatic tumor-related hypercalcemia: a prospective randomized crossover trial
01.09.1992Ann Oncol 1992; 3:619-23
Thürlimann Beat, Waldburger R, Senn H J, Thiébaud D
Effective prevention of chemotherapy--induced phlebitis by low-dose heparin: a prospective randomised trial
Thürlimann B, Bachmann I. Effective prevention of chemotherapy--induced phlebitis by low-dose heparin: a prospective randomised trial. Ann Oncol 1992; 3:311-3.
01.04.1992Effective prevention of chemotherapy--induced phlebitis by low-dose heparin: a prospective randomised trial
01.04.1992Ann Oncol 1992; 3:311-3
Thürlimann Beat, Bachmann I
[Peripheral spontaneous remission of hairy cell leukemia following transfusion-associated hepatitis C]
Morant R, Thürlimann B, Jungi W, Schmid L, Holdener E, Schmid U, Senn H. [Peripheral spontaneous remission of hairy cell leukemia following transfusion-associated hepatitis C]. Schweiz Med Wochenschr 1991; 121:344-6.
09.03.1991[Peripheral spontaneous remission of hairy cell leukemia following transfusion-associated hepatitis C]
09.03.1991Schweiz Med Wochenschr 1991; 121:344-6
Morant R, Thürlimann Beat, Jungi W F, Schmid L, Holdener E, Schmid U, Senn H J
Recombinant human granulocyte-macrophage colony-stimulating factor for the intensification of cytostatic treatment in advanced cancer
Schmid L, Thürlimann B, Müller M, Senn H. Recombinant human granulocyte-macrophage colony-stimulating factor for the intensification of cytostatic treatment in advanced cancer. Recent Results Cancer Res 1991; 121:173-81.
01.01.1991Recombinant human granulocyte-macrophage colony-stimulating factor for the intensification of cytostatic treatment in advanced cancer
01.01.1991Recent Results Cancer Res 1991; 121:173-81
Schmid L, Thürlimann Beat, Müller M, Senn H J
Ceftriaxone and amikacin versus ceftazidime and amikacin in febrile granulocytopenia
Schmid L, Jeschko M, Wilder-Smith C, Schafroth U, Thürlimann B, Pedrazzini A, Senn H. Ceftriaxone and amikacin versus ceftazidime and amikacin in febrile granulocytopenia. Chemotherapy 1991; 37:346-52.
01.01.1991Ceftriaxone and amikacin versus ceftazidime and amikacin in febrile granulocytopenia
01.01.1991Chemotherapy 1991; 37:346-52
Schmid L, Jeschko M, Wilder-Smith C, Schafroth U, Thürlimann Beat, Pedrazzini A, Senn H
Anthracycline-carboplatin combination in metastatic breast cancer
Thürlimann B, Senn H, Jungi W. Anthracycline-carboplatin combination in metastatic breast cancer. J Cancer Res Clin Oncol 1990; 116:13-4.
01.01.1990Anthracycline-carboplatin combination in metastatic breast cancer
01.01.1990J Cancer Res Clin Oncol 1990; 116:13-4
Thürlimann Beat, Senn H J, Jungi W F
[Safety problems in the handling of cytostatics]
Thürlimann B, Senn H. [Safety problems in the handling of cytostatics]. Ther Umsch 1988; 45:403-7.
01.06.1988[Safety problems in the handling of cytostatics]
01.06.1988Ther Umsch 1988; 45:403-7
Thürlimann Beat, Senn H J
Aspergillus brain abscess. A case report
Coccia-Portugal M, Sieling W, Terblanche A, Thürlimann B, van Rensburg P, Greyling S, Stevens K, Heyneke P, Falkson G. Aspergillus brain abscess. A case report. S Afr Med J 1987; 71:116-8.
24.01.1987Aspergillus brain abscess. A case report
24.01.1987S Afr Med J 1987; 71:116-8
Coccia-Portugal M A, Sieling W L, Terblanche A P, Thürlimann Beat, van Rensburg P G, Greyling S A, Stevens K, Heyneke P J, Falkson G